Clinical Trials
477 trialsNCT06876142 2026-05-27
Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma
National Institutes of Health Clinical Center (CC)
Phase 1/2 Suspended
NCT05714839 2026-05-22
DREAMM-20
GlaxoSmithKline
Phase 1/2 Recruiting
NCT07601100 2026-05-22
Isa Iber VD
Dana-Farber Cancer Institute
Phase 1/2 Not yet recruiting
NCT07600151 2026-05-20
CONQUISTADOR
Universitätsklinikum Hamburg-Eppendorf
Phase 1/2 Not yet recruiting
NCT04824794 2026-05-19
GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies
Genmab
Phase 1/2 Terminated
NCT06239272 2026-05-19
NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)
St. Jude Children's Research Hospital
Phase 1/2 Recruiting
NCT05853965 2026-05-18
BELI(E)VE
Universitätsklinikum Hamburg-Eppendorf
Phase 1/2 Recruiting
NCT07116616 2026-05-18
A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
ModernaTX, Inc.
Phase 1/2 Recruiting
NCT07479979 2026-05-14
Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma
Hoosier Cancer Research Network
Phase 1/2 Recruiting
NCT02362035 2026-05-13
KEYNOTE145
Acerta Pharma BV
Phase 1/2 Completed
NCT05002816 2026-05-13
Novel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic Efficacy in Multiple Myeloma
Yale University
Phase 1/2 Active not recruiting
NCT05514990 2026-05-13
Bortezomib and Pembrolizumab With or Without Pelareorep for the Treatment of Relapsed or Refractory Multiple Myeloma, AMBUSH Trial
University of Southern California
Phase 1/2 Active not recruiting
NCT05828511 2026-05-13
LINKER-MM4
Regeneron Pharmaceuticals
Phase 1/2 Recruiting
NCT06066359 2026-05-13
Ph I/II Trial of Cord Blood-derived NK Cells With NY-ESO-1 TCR/IL-15 for R/R Myeloma
M.D. Anderson Cancer Center
Phase 1/2 Recruiting
NCT07463807 2026-05-13
Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment
National Cancer Institute (NCI)
Phase 1/2 Not yet recruiting
NCT04973605 2026-05-11
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
BeOne Medicines
Phase 1/2 Recruiting
NCT05060627 2026-05-11
Study of Belantamab Mafodotin in Combination With Kd for the Treatment of Relapsed Myeloma Patients, Refractory to Lenalidomide
PETHEMA Foundation
Phase 1/2 Active not recruiting
NCT05145816 2026-05-07
Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis
University of Texas Southwestern Medical Center
Phase 1/2 Recruiting
NCT05535244 2026-05-07
CAMMA 2
Hoffmann-La Roche
Phase 1/2 Active not recruiting
NCT04126200 2026-05-06
DREAMM 5
GlaxoSmithKline
Phase 1/2 Active not recruiting
NCT05092451 2026-05-06
Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
M.D. Anderson Cancer Center
Phase 1/2 Recruiting
NCT05850234 2026-05-06
DURGA-1
AstraZeneca
Phase 1/2 Recruiting
NCT06106945 2026-05-06
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma
AstraZeneca
Phase 1/2 Recruiting
NCT07084896 2026-05-06
Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat in Participants With RRMM
GlaxoSmithKline
Phase 1/2 Active not recruiting
NCT02343042 2026-05-04
STOMP
Karyopharm Therapeutics Inc
Phase 1/2 Active not recruiting
NCT04083534 2026-05-04
First In Human (FIH) Study of REGN5459 in Adult Patients With Relapsed or Refractory Multiple Myeloma (MM)
Regeneron Pharmaceuticals
Phase 1/2 Completed
NCT05583617 2026-05-04
PLYCOM
Hoffmann-La Roche
Phase 1/2 Recruiting
NCT06292780 2026-04-29
LINKER-AL2
Regeneron Pharmaceuticals
Phase 1/2 Recruiting
NCT06429150 2026-04-24
Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or Plasmacytoma
Shenzhen Geno-Immune Medical Institute
Phase 1/2 Recruiting
NCT05392946 2026-04-21
Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma, IDEAL Study
Mayo Clinic
Phase 1/2 Active not recruiting
NCT03761108 2026-04-20
LINKER-MM1
Regeneron Pharmaceuticals
Phase 1/2 Recruiting
NCT04822337 2026-04-16
Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma
Wake Forest University Health Sciences
Phase 1/2 Active not recruiting
NCT05434689 2026-04-15
COMMANDER
University of Alabama at Birmingham
Phase 1/2 Active not recruiting
NCT07455851 2026-04-15
A Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants With Relapsed/Refractory Multiple Myeloma
Regeneron Pharmaceuticals
Phase 1/2 Recruiting
NCT03192397 2026-04-14
Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant
Roswell Park Cancer Institute
Phase 1/2 Active not recruiting
NCT06669247 2026-04-13
COSTIMM
Regeneron Pharmaceuticals
Phase 1/2 Recruiting
NCT07523555 2026-04-13
ADAPT-HEM
Beijing Biotech
Phase 1/2 Recruiting
NCT01054196 2026-04-08
Lenalidomide Plus Melphalan as a Preparative Regimen for Autologous Stem Cell Transplantation in Relapsed Multiple Myeloma: A Phase 1 / 2 Study
Weill Medical College of Cornell University
Phase 1/2 Active not recruiting
NCT01502085 2026-04-03
RZD
Hackensack Meridian Health
Phase 1/2 Completed
NCT02681302 2026-04-03
CPIT001
Hackensack Meridian Health
Phase 1/2 Terminated
NCT06536413 2026-04-03
ATRA
The Methodist Hospital Research Institute
Phase 1/2 Recruiting
NCT07510100 2026-04-03
FUMANBA-04
Nanjing IASO Biotechnology Co., Ltd.
Phase 1/2 Not yet recruiting
NCT01242267 2026-04-02
Thal/Mel/Vel
Hackensack Meridian Health
Phase 1/2 Completed
NCT07181941 2026-03-27
Response-Based Dose Reduction of Linvoseltamab in the Treatment of Relapsed, Refractory, or Triple-Class Relapsed/Refractory Multiple Myeloma
Fred Hutchinson Cancer Center
Phase 1/2 Recruiting
NCT06232044 2026-03-25
Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma
Alliance for Clinical Trials in Oncology
Phase 1/2 Recruiting
NCT04988555 2026-03-24
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Sumitomo Pharma America, Inc.
Phase 1/2 Recruiting
NCT07081646 2026-03-24
ALACRITY
Alexion Pharmaceuticals, Inc.
Phase 1/2 Recruiting
NCT01297764 2026-03-23
QUAD
Hackensack Meridian Health
Phase 1/2 Active not recruiting
NCT02773030 2026-03-20
A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma
Celgene
Phase 1/2 Active not recruiting
NCT03441958 2026-03-18
ECT-001 (UM171) Expanded Cord Blood Transplant to Treat High-risk Multiple Myeloma
Ciusss de L'Est de l'Île de Montréal
Phase 1/2 Completed